Crescita Therapeutics Inc. (CRRTF)
CRRTF Stock Price Chart
Explore Crescita Therapeutics Inc. interactive price chart. Choose custom timeframes to analyze CRRTF price movements and trends.
CRRTF Company Profile
Discover essential business fundamentals and corporate details for Crescita Therapeutics Inc. (CRRTF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
11 Apr 2016
Employees
—
CEO
Serge Verreault
Description
Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. The company operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. It owns proprietary platform technologies, including MMPE and DuraPeel for the development of topicals containing cannabis and hemp. The company's prescription products include Pliaglis, a topical local anesthetic cream that provides dermal analgesia on intact skin prior to superficial dermatological procedures; CTX-101, a Phase III topical formulation utilizing a corticosteroid in combination with MMPE technology to treat plaque psoriasis; CTX-102, a Phase I topical formulation utilizing MMPE technology to treat an undisclosed dermatological skin condition; and dermatology products in pre-clinical formulation utilizing MMPE technology for prescription treatments of skin diseases. Its non-prescription skincare products comprise skincare products, such as facial creams, cleansers, exfoliants, masks, serums, and suncare products for aging, acne, rosacea, pigmentation, dehydration, and sensitivity under the Laboratoire Dr Renaud brand; a line of dermocosmetic products for anti-aging medical procedures under the Pro-Derm brand; a line of products to target and treat various skincare concerns under the Alyria brand; and skincare products primarily for the Asian consumers under Dermazulene brand, as well as NCTF 135 HA, a skin revitalization solution primarily used for the improvement of skin quality and fine lines. The company has a development and licensing agreement with Sundial Growers Inc. to develop cannabis; a commercialization license agreement with Cantabria Labs Inc.; and a development and commercialization license agreement with Taro Pharmaceuticals Inc. Crescita Therapeutics Inc. was incorporated in 2016 and is headquartered in Laval, Canada.
CRRTF Financial Timeline
Browse a chronological timeline of Crescita Therapeutics Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 May 2026
Upcoming earnings on 16 Mar 2026
Upcoming earnings on 4 Nov 2025
Earnings released on 6 Aug 2025
Earnings released on 14 May 2025
EPS came in at -$0.03 , while revenue for the quarter reached $2.48M .
Earnings released on 18 Mar 2025
EPS came in at -$0.01 , while revenue for the quarter reached $4.80M .
Earnings released on 6 Nov 2024
EPS came in at -$0.04 , while revenue for the quarter reached $2.65M .
Earnings released on 7 Aug 2024
EPS came in at -$0.03 , while revenue for the quarter reached $2.99M .
Earnings released on 8 May 2024
EPS came in at -$0.02 , while revenue for the quarter reached $3.68M .
Earnings released on 13 Mar 2024
EPS came in at -$0.01 , while revenue for the quarter reached $3.56M .
Earnings released on 8 Nov 2023
EPS came in at -$0.05 , while revenue for the quarter reached $2.24M .
Earnings released on 9 Aug 2023
EPS came in at -$0.01 , while revenue for the quarter reached $3.90M .
Earnings released on 11 May 2023
EPS came in at -$0.01 , while revenue for the quarter reached $3.40M .
Earnings released on 15 Mar 2023
EPS came in at $0.04 , while revenue for the quarter reached $4.49M .
Earnings released on 9 Nov 2022
EPS came in at $0.01 , while revenue for the quarter reached $4.40M .
Earnings released on 10 Aug 2022
EPS came in at -$0.00 , while revenue for the quarter reached $5.06M .
Earnings released on 11 May 2022
EPS came in at $0.03 , while revenue for the quarter reached $5.93M .
Earnings released on 31 Mar 2022
EPS came in at -$0.02 , while revenue for the quarter reached $3.96M .
Earnings released on 11 Nov 2021
EPS came in at -$0.03 , while revenue for the quarter reached $2.38M .
Earnings released on 30 Sept 2021
EPS came in at -$0.03 , while revenue for the quarter reached $2.36M .
Earnings released on 11 May 2021
EPS came in at -$0.02 , while revenue for the quarter reached $2.60M .
Earnings released on 24 Mar 2021
EPS came in at $0.15 , while revenue for the quarter reached $5.48M .
Earnings released on 31 Dec 2020
EPS came in at -$0.02 , while revenue for the quarter reached $2.19M .
CRRTF Stock Performance
Access detailed CRRTF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.